A single centre randomised double blind placebo controlled 12 week trial in subjects with type 2 diabetes comparing glycaemic control with insulin glargine in combination with nateglinide or placebo

Completed

• Conditions: utritional, Metabolic, Endocrine: Diabetes; Nutritional, Metabolic, Endocrine; Diabetes

• Registration Number: ISRCTN10167754
• Lead Sponsor: Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09-29
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 55

Inclusion Criteria

1. Aged 18 years or over
2. Type 2 diabetes (meeting the WHO definition of diabetes)
3. Using a human premix or NPH insulin for at least 3 months
4. HbA1c of 6.1-10.0 %
5. BMI inferior or equal to 42.0 kg/m2
6. Both men & women were eligible for recruitment, but women of childbearing potential were required to be using adequate contraception

Exclusion Criteria

1. Significant hepatic dysfunction
2. Significant renal dysfunction
3. Active cardiovascular disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified